Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans

Objective Our objective was to define the pharmacodynamic profile of the new dual neutral endopeptidase (NEP)/angiotensin‐converting enzyme (ACE) inhibitor AVE7688. Methods We compared the effects of single oral doses of AVE7688 (5 and 25 mg) with those of 10 mg ramipril (R10), a selective ACE inhib...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2006-01, Vol.79 (1), p.49-61
Hauptverfasser:	Azizi, Michel, Bissery, Alvine, Peyrard, Séverine, Guyene, Than Tam, Ozoux, Marie‐Laure, Floch, Anne, Ménard, Joël
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aldosterone - urine Angiotensin II Type 1 Receptor Blockers - pharmacology Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics Angiotensin-Converting Enzyme Inhibitors - pharmacology Atrial Natriuretic Factor - urine Biological and medical sciences Biotransformation Biphenyl Compounds - pharmacology Cross-Over Studies Cyclic GMP - urine Dose-Response Relationship, Drug Heterocyclic Compounds, 3-Ring - pharmacokinetics Heterocyclic Compounds, 3-Ring - pharmacology Humans Male Medical sciences Natriuresis - drug effects Oligopeptides - urine Peptidyl-Dipeptidase A - blood Pharmacology. Drug treatments Protease Inhibitors - pharmacokinetics Protease Inhibitors - pharmacology Ramipril - pharmacology Renin - blood Renin-Angiotensin System - drug effects Single-Blind Method Tetrazoles - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!